DIN 02502712 — DARZALEX SC 1800 MG
DARZALEX SC is a solution of Daratumumab marketed by JANSSEN INC. The full Daratumumab monograph covers indications, dosing, interactions and counselling for every strength and manufacturer.
- DIN
- 02502712
- Brand name
- DARZALEX SC
- Active ingredient
- Daratumumab
- Strength
- 1800 MG
- Dosage form
- SOLUTION
- Route
- SUBCUTANEOUS
- Manufacturer
- JANSSEN INC
- Health Canada status
- MARKETED
- Drug class
- CD38-directed monoclonal antibody (antineoplastic)
Product data from the Health Canada Drug Product Database, synced . Verify the live status at Health Canada.
Other Daratumumab products
| DIN | Brand | Strength | Form | Manufacturer | Status |
|---|---|---|---|---|---|
| 02455951 | DARZALEX | 100 MG | SOLUTION | JANSSEN INC | MARKETED |
| 02455978 | DARZALEX | 400 MG | SOLUTION | JANSSEN INC | MARKETED |